Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs,...

Full description

Bibliographic Details
Main Authors: Andreas Blesl, Elisabeth Krones, Marion J. Pollheimer, Johannes Haybaeck, Ulrike Wiesspeiner, Rainer W. Lipp, Patrizia Kump
Format: Article
Language:English
Published: Karger Publishers 2017-12-01
Series:Case Reports in Oncology
Subjects:
Neuroendocrine tumor
Chemotherapy
Liver biopsy
mTor
Somatostatin
Online Access:https://www.karger.com/Article/FullText/484473

Internet

https://www.karger.com/Article/FullText/484473

Similar Items